Skip to main content

The Government of Canada has granted a startup the authority to export psychedelic substances to Australia for medicinal purposes. Tasked with this responsibility is Optimi Health Corp., who authorized by the health department, will be shipping pills containing psilocybin, a magic mushroom extract, and MDMA.

The growing demand isn’t limited to local magic mushrooms Ontario. Other countries are following Canada’s lead, starting to investigate and authorize the medicinal application of serotogenic compounds.

Securely order psychedelics online in Canada and tap into your inherent potential through trustworthy sources.

[toc]

Key Points:

  • Vancouver-based startup Optimi Health has been issued a drug establishment license to export magic mushroom pills to Australia.
  • In Australia, licensed psychiatrists are allowed to use magic mushrooms in addressing chronic depression.
  • Treatment typically consists of three sessions spread over five to eight weeks, with each session lasting about eight hours.
Magic mushrooms Ontario in Canada

The Rise of Psilocybin Capsules in Canada

Optimi, a startup company based in Vancouver, aims to capitalize on its certification to broaden the pharmaceutical market for psychedelic drugs and secure a first-mover advantage.

Seven companies have exported psilocybin, MDMA, or both, but only for clinical trial purposes. A spokesperson from Canada’s health department could not confirm if these exports were for regular patient use and declined to reveal the companies for security reasons.

This accomplishment places Optimi among a limited group of global suppliers, with the current market favoring clinical over recreational use.

What Does the Pill Contain?

Although the company hasn’t disclosed the specific mushroom used in the pill, it works with a range of strains including Albino Penis Envy, among others.

Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, examine, and extract its psychedelic mushrooms. Situated three hours east of Vancouver, this quaint town is home to about 3,000 residents.

How Australia and Psychedelic Mushrooms Interrelate

It’s estimated that one in every five Australians between the ages of 16 and 85 may suffer from a mental illness at some point. PTSD (post-traumatic stress disorder) could impact 11% of Australians, while anxiety disorders are common amongst 17% of the population.

While a myriad of treatment options for mental disorders exist, not all are effective for everyone. Those who don’t respond to specific treatments often struggle to find a method that works for them, thus making them more vulnerable.

Understanding the Process

Australia has taken the lead in the use of psilocybin, allowing licensed psychiatrists to employ this regulated substance to treat treatment-resistant PTSD and depression.

In an unexpected move in February, the Therapeutic Goods Administration (TGA) of Australia reclassified MDMA and magic mushrooms for therapeutic use. They asserted that these substances are safe when used in a medically supervised environment for patients with serious mental health issues.

This breakthrough has been a game-changer for many mental health professionals and researchers. The use of these substances will be rigorously monitored; it’s not as simple as just taking a pill and leaving.

The treatment regimen typically consists of three sessions held over five to eight weeks. Each session lasts approximately eight hours, with the therapist staying with the patient for the entire duration.

Canada’s Role in Advancing Psilocybin Research

Canada has become a significant center for psilocybin research, substantially expanding our understanding of this compound. Health Canada and several institutions are at the forefront of exploring the therapeutic potentials of psilocybin in treating various mental health conditions.

Research institutions are no longer obliged to classify these substances as illegal or rely on unauthorized dispensaries or mushroom outlets. The government now permits certain institutions to grow mushrooms for research.

The increased accessibility to substances formerly deemed harmful enables researchers to deepen their understanding of their potential benefits to numerous individuals.

A Cyclical Trend

The field showing promise for treating mental health and substance abuse issues, including alcoholism, was initially explored in the 1950s. The pioneers of this innovative research were English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer, who worked at Saskatchewan’s Weyburn Mental Hospital. Under the leadership of then-premier Tommy Douglas, the medical community was granted substantial freedom to investigate their medical hypotheses, leading to significant advancements.

Dr. Osmond and Dr. Hoffer initiated studies using LSD, mescaline, and peyote as potential alternatives to the harsh methods of electroshock and lobotomy. Their research took unexpected turns, leading them to promote the experimental use of these drugs among doctors, nurses, and other healthcare staff.

Canadian Institutes of Health Research 

The Canadian Institutes of Health Research, through the Institute of Neurosciences, Mental Health and Addiction, is funding three clinical trials. These trials aim to assess the therapeutic potential and safety of psilocybin-assisted psychotherapy

Project TypeStudy FocusResearch Institution Principal InvestigatorProject Budget 
A randomized controlled trialAddressing psychological distress in terminal cancer patientsUniversity of TorontoSarah Hales$928,643
Understanding mechanisms behind psilocybin psychotherapy for alcohol use disorder treatmentAlcohol use disorderUniversity of CalgaryLeah Mayo$1,000,000
A randomized phase II clinical trial comparing single versus dual psychedelic dosesTreatment-resistant depressionUniversity of TorontoJoshua Rosenblat$1,000,000

This research funding will enable a better understanding of the potential benefits of controlled substances. The Canadian Drugs and Substances Strategy (CDSS), initiated by the Government of Canada, has made this funding possible. 

Further Psychedelic Research

In Vancouver, psychiatrists have started a phase III clinical trial using MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment plan involves three eight-hour sessions with MDMA, spaced a month apart, plus nine 90-minute sessions without the drug. Researchers consider this trial ground-breaking, as it marks the first clinical evaluation of an illegal substance.

It’s been over forty years since we’ve seen a psychedelic substance like this.

Deciphering Psilocybin

Psilocybin is a psychedelic compound that naturally occurs in certain species of mushrooms. Upon ingestion, it transforms into psilocin. This psilocin then stimulates the serotonin 5-HT2a receptors found on the brain’s cortical pyramidal cells, which are key to processing information. 

Local authorities are currently studying the substance for its capability to aid with depression, anxiety, addiction, and end-of-life distress, by promoting introspection and spiritual enlightenment.

Why is it Potentially Effective for Depression, PTSD, and Other Conditions?

Its active component targets various areas of the brain, making it potentially beneficial for a range of mental disorders. Numerous patients in Canada and Australia have already undergone this treatment, and the results show potential, with minor side-effects such as temporary anxiety or increased blood pressure.

Impact on Neurobiology

  • Activation of Serotonin Receptors: This substance functions as a partial agonist at serotonin receptors, specifically the 5-HT2A subtype, which is vital for emotional processing and mood regulation.
  • Default Mode Network (DMN) Adjustment: It reduces activity in the DMN, promoting introspection, mitigating rigid thought patterns, and encouraging emotional flexibility.
  • Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of the substance are due to its influence on the prefrontal and limbic regions of the brain, including the amygdala. In depression cases, individuals usually show decreased responsiveness to emotional stimuli. The substance enhances the response to positive emotional stimuli in the right amygdala and minimizes or normalizes the response to negative or neutral emotional stimuli.

Psychological and Emotional Effects:

  • Creation of Positive Mood States: It stimulates feelings of euphoria, interconnectedness, and emotional openness during and post the experience.
  • Enhanced Emotional Processing: The psychedelic experience might allow individuals to safely face and process deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
  • Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College London suggests that this could result in long-term positive changes such as improved well-being, increased life satisfaction, and spiritual growth.

What Can You Discover at Your Nearby Magic Mushroom Store?

Interested in how this substance can affect your mental health? Visit magic mushroom stores to find a product that suits your requirements.

ProductQuantityPotencyBenefits
Evoke – Medicinal Mushrooms20100mg or 200mgImproves mood, encourages creative thinking, and enhances productivity and focus
Ground Sounds – Microdose Capsules – Super Freak3050mg, 100mg, and 250mgBoosts wellness and elevates overall quality of life
Kind Stranger – Microdose Capsules – Sidekick30100mgEncourages clarity, creativity, and concentration. Contains a powerful mix of clinical strength adaptogenic herbs
Osmosis – Brain Boost30100mg or 200mgDelivers cognitive and energy enhancements

Worldwide Acceptance of Psilocybin

Canada isn’t the sole country advocating for the use of magic mushrooms for mental health troubles. Countries like Australia are also embracing these hallucinogens to tackle issues such as depression and PTSD. They are obtaining top-notch psychedelic capsules from trustworthy sources. With the right supervision, patients can significantly improve their life quality. Buy Magic Mushrooms Canada, a magic mushroom supplier, offers a variety of products, from pills to LSD edibles.

Frequently Asked Questions

How do psilocybin and MDMA compare?

Both psilocybin and MDMA have therapeutic potential for enhancing mental health. Psilocybin interacts with serotonin 2A receptors and is effective for treating depression and addiction.

Meanwhile, MDMA promotes empathy and is beneficial in PTSD therapy. It has the potential to enhance emotional processing and

Despite being classified as a controlled substance, it has shown promising therapeutic results.

Is this treatment option accessible to all Australians?

No. In Australia, individuals must undergo an assessment first to determine their eligibility to use the substance. This assessment takes into account factors like pre-existing heart conditions, history of psychosis, and others. Only patients who have not responded to conventional treatments for conditions such as depression, anxiety, or PTSD are considered for this treatment.

What are the implications of Canada exporting mushrooms?

Canada is strategically positioning itself to lead the psychedelics market, mirroring its approach to cannabis. This move could encourage more companies to produce top-quality products. As a result, Canada might establish itself as a leader in the hallucinogen market, strengthen its economy, and make treatments more accessible to other countries. It could also prevent other nations from obtaining their hallucinogens from illegal dispensaries or suppliers, thereby maintaining safety.

Interesting Articles for You to Read: